Take action against Alzheimer’s

Do you want to take action against Alzheimer’s, just like me? See below the full overview of our studies.

What we’ve achieved so far

75+

Trials

250+

Participants

3

Locations

Our Alzheimer’s trials

Filter

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle

All trialsAlzheimer

Together

The goal of this study is to evaluate the safety and potential effectiveness of the…

The goal of this study is to evaluate the safety and potential effectiveness of the investigational drug (bepranemab) for participants with MCI or mild Alzheimer’s Disease. The study compares the effect of the active study drug bepranemab with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). Using a placebo will help us identify improvements or side effects which are caused by the active study medication. The study drug is administered through an intravenous (IV) injection.

audience50 - 80 years

levelMild cognitive impairment (MCI) or mild Alzheimer’s disease

duration152 weeks

locationAmsterdam, Den Bosch, and Zwolle

Alzheimer

TA-8995-AD-1 New Amsterdam Pharma

The goal of this research is to find out how safe and potentially effective the new drug obicetrapib is for…

The goal of this research is to find out how safe and potentially effective the new drug obicetrapib is for the treatment of participants with early-stage Alzheimer’s disease (mild cognitive impairment or beginning dementia). The research drug is taken in the form of a tablet.

audience50-75 years

levelEarly stage of Alzheimer’s

duration36 weeks

locationAmsterdam

All trialsAlzheimer

Autonomy

A phase II, double-blind, randomized, placebo-controlled study, parallel-group, multicenter research on the safety and effectiveness…

A phase II, double-blind, randomized, placebo-controlled study, parallel-group, multicenter research on the safety and effectiveness of JNJ-63733657. A monoclonal anti-tau-antibody, to be tested with participants in the early stages of Alzheimer’s disease.

audience55 - 80 years (M/F)

levelEarly stage of Alzheimer's

duration4.5 years

locationAmsterdam, Den Bosch and Zwolle

All trialsAlzheimer

Alector AD

A phase II, multicentre, double-blind, randomized, placebo-controlled study of the safety and efficacy of the…

A phase II, multicentre, double-blind, randomized, placebo-controlled study of the safety and efficacy of the drug AL002 in participants with mild to moderate Alzheimer's disease.

audience50 - 85 years (M / F)

levelDementia due to Alzheimer's disease

duration112 weeks

locationAmsterdam, Den Bosch and Zwolle

All trialsAlzheimer

Open Road

An open-label, multicenter, follow-up study to evaluate the safety and tolerability of long-term administration of…

An open-label, multicenter, follow-up study to evaluate the safety and tolerability of long-term administration of Gantenerumab in subjects with Alzheimer's disease.

audience50 - 85 years (M/F)

levelDementia due to Alzheimer's disease

duration2 years

locationAmsterdam

All trialsAlzheimer

Embark

Phase IIIb, open-label, multicenter safety study of BIIB037 (aducanumab) in study participants with Alzheimer's disease…

Phase IIIb, open-label, multicenter safety study of BIIB037 (aducanumab) in study participants with Alzheimer's disease who previously participated in the aducanumab studies: 221AD103, 221AD301, 221AD302, and 221AD205.

audience50 - 85 years (M / F)

levelDementia due to Alzheimer's disease

duration2,5 years

locationAmsterdam

All trialsAlzheimer

Alector FTD

A multicenter, open-label phase II study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of…

A multicenter, open-label phase II study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in heterozygous carriers of C9orf72 mutations leading to frontotemporal dementia.

audience18 - 85 years (M / F)

levelGenetically confirmed C9orf72 mutation

duration112 weeks

locationAmsterdam

Let us know how we can help you

Do you have any questions or would you like to know more about one of our studies? Contact us by phone or email. We are happy to help you.

What do our participants say?

“The most important thing is that there is a solution.”

“With my participation, I may also help others,” says Mr. Arts, one of our participants.

Our partners

Our mission is to eliminate brain diseases, but we cannot do that alone. That is why we work together with leading partners.